About RI Technologies

RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development.

Research As Good as the Methodology is!

Gauging Competitive Intelligence Identifying Key Growth Areas and Opportunities Understanding Geographic Relevance to Product Knowing Regional Market Sizes and Growth Opportunities and Restraints Keeping Tab on Emerging Technologies Equity Analysis Tapping New Markets

COPYRIGHT
The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company.

DISCLAIMER
RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.
MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 1

MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 2

II. REPORT SYNOPSIS

Stem Cells in Cardiology
The Role of Stem Cells in Repairing the Heart A study was recently conducted wherein it was conclusively proved that stem cell therapies do have a future role to play in the repairing of the heart. Human adult stem cells extracted from the bone marrow can produce vascular endothelial cells after their transplantation is effected into rats. In one such study using the rat model, the left anterior descending coronary artery was manually constricted and thus a heart attack was induced. A population of human hematopoietic stem cells was diligently identified as they obviously cause the production of new blood vessels. This investigation was similar to the Jackson study. The stem cells were seen to exhibit the property of plasticity. Now, plasticity in stem cells signifies that the cells could develop into cell types that they would routinely not tend to become. These stem cells were then made use of in the formation of new blood vessels in the damaged portions of the heart. Thereby, proliferation of the preexisting vasculature was encouraged, following the induced heart attack. Thus, it is observed that human hematopoietic stem cells have the potential to develop into an array of tissue types including cardiac musculature given the suitable culture conditions. The human hematopoietic stem cells were first injected into the bloodstream that entered into the damaged heart of the rat model. It was noted that these cells could obviate the cessation of the thickened or hypertrophied myocardial cells. These myocardial cells though damaged were viable. The investigation also noted the reduction of the progressive development of collagen scars and fibers. The other groups of rats, which were surgically treated in a controlled condition, that had their left anterior descending coronary arteries intact, or those, that had their left anterior descending coronary arteries ligated, were observed. It was found that those control rats that were injected with control cells or saline did not exhibit any enhancement in their quantity of blood vessels. The identification of the hematopoietic cells could be performed on the basis of highly specific cell markers. Eventually, it is possible to differentiate them from cardiomyocyte precursor cells. Thus the cells can be utilized as they are, or in association with other pharmacological therapies, or myocyte-regeneration designs. Human embryonic stem cell research is a subject that is attracting immeasurable attention. So much so, that new findings in the area of cardiomyocyte regeneration are regularly taking place. Human embryonic stem cells have shown their capability to differentiate into any cell type in the adult human body and have therefore become a new source population presenting the potential to change into cardiac-repair cells.
MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 3

This was pioneered by Itskovitz-Eldor and associates who showed the world that the human embryonic stem cells can reproducibly differentiate, given appropriate culture, into embryoid bodies comprising of cell types, which exist in the human bodys three embryonic germ layers. Among the different cell types, can be found cells that exhibited the physical appearance of cardiomyocytes. These cells showed cellular markers that had the properties of heart cells. When they were carefully studied under a microscope, they were found to demonstrate contractile activity akin to cardiomyocytes. At the early part of research activity in this field, the functional and structural attributes of the initial stage of cardiomyocytes in the cells that develop from the embryoid bodies, were displayed. Those cells that exhibit contracting activity readily were identified with the use of markers. The markers were used with antibodies to proteins that exist in the heart tissue. The proteins in the heart tissue are cardiac troponin, antinaturietic protein, desmin, myosin heavy chain and alpha-actinin. Upon conducting a genetic analysis of these cells it was noticed that the transcription-factor genes that were expressed were in conformity with early stage cardiomyocytes. The electrical recordings from these cells were then carefully observed. In this study, it was seen that changes did take place in the calcium-ion movement inside the cells. Another factor namely, the contractile responsiveness to catecholamine hormone stimulation by the cells was studied. It was found that these observations were akin to responsiveness, changes and recordings that were made in early cardiomyocytes, when mammalian development was being investigated into. Segmentation of Stem Cells in Cardiology Exhibit: Segmentation of Global Stem Cells Market in Cardiology by Source and by Type
Source Allogenic Autogenic *Cord Blood Cells etc. RIT, 2011

Stem Cell Type Bone Marrow Stem Cells Embryonic Stem Cells *Other

MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 4

STEM CELL GLOBAL MARKET ANALYSIS Global Stem Cells market is projected to reach about US$XX.XX billion by 2015 from an estimated US$XX.XX billion in 2010, growing at a robust compounded annual growth rate (CAGR) of XX.XX% during the analysis period 2005-2015. Exhibit: Stem Cells - Global Value Market Estimations & Predictions in US$ Million
Year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 CAGR% RIT Figures, 2011 Value XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX

MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 5

STEM CELL GLOBAL MARKET ANALYSIS Global Stem Cells in Cardiology market is projected to reach about US$XX.XX billion by 2015 from an estimated US$XX.XX billion in 2010, growing at a robust compounded annual growth rate (CAGR) of XX.XX% during the analysis period 2005-2015. Exhibit: Stem Cells in Cardiology - Global Value Market Estimations & Predictions in US$ Million
Year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 CAGR% RIT Figures, 2011 Value XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX

MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 6

Exhibit: List of Major Global Companies

Company Aastrom Biosciences, Inc. Advanced Cell Technology, Inc. Axordia Limited Cellartis AB CellSeed, Inc. CordLife Ltd Gamida Cell Ltd. More
RIT, 2011

Regio n USA USA UK Swede n Japan Austral ia Israel

Website www.aastrom.com www.advancedcell .com www.axordia.com www.cellartis.com www.cellseed.com www.cygenics.com www.gamidacell.com

Exhibit1.: Stem Cells Market in Cardiology by Source - Global Value Market Estimations & Predictions (2005 2015) for Allogenic and Autogenic Stem Cell Transplantation in US$ Million
Year/Regio n 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 CAGR% RIT, 2011 Allogenic XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX Autoge nic XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX Total XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX

MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 7

Global Market Analysis Global market for stem cells is projected to reach about US$XX.XX billion by 2015 from an estimated US$ XX.XX billion in 2010, growing at a Compounded Annual Growth Rate (CAGR) of XX.XX % during the analysis period, 2005-2015. North America is projected as the largest market for stem cells for 2009 with a share of slightly over one-third of global market valued at US$ XX.XX billion and is projected to reach US$ XX.XX billion by 2015 to retain its position with a share of XX.XX %. Europe is projected to be the second largest (XX.XX % market share in 2009) and second fastest growing (CAGR of XX.XX % during 2005-2015) market, while AsiaPacific is projected to be the fastest growing (XX.XX % during 2005-2015) market. In 2009, the market for stem cells in Europe and Asia-Pacific is estimated at US$ XX.XX billion and US$ XX.XX billion respectively. Rest of World regions market is expected to be US$ XX.XX billion for 2009. Exhibit2.: Stem Cells - Global Value Market Estimations & Predictions (2005 2015) by Geographic Region for North America, Europe, AsiaPacific and Rest of World in US$ Billion
Year /Region 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 CAGR% RIT Figures, 2011 North America XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX Europe XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX Asia-Pacific XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX Rest of World XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX Total XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX

MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 8

STEM CELLS

IN

CARDIOLOGY INDUSTRY OUT LOOK

The concept of stem cell transplantation to regenerate the myocardium and better the working of the heart has received a great deal of attention in recent times. Small-scale studies in the pre-clinical and clinical stages support the use of stem cells in treating heart disease. However similar such studies must be carried out on a larger-scale to corroborate the findings and prove stem cell therapy as a viable alternative method of treating patients with heart disease. Cells in hearts muscle are not capable of replacing themselves, and therefore the heart does not return to normal functioning levels once some of these cells are damaged. Other than stem cells therapy and surgery, there are hardly any effective methods available for treating cardiovascular ailments. This leaves people with congestive heart failure, heart attack, and congenital heart diseases with little hope to improve their quality of life. Though transplanting of heart is an effective technique, donors of heart are few in number. This is where adult stem cell therapy comes in. Adult stem cells are able to coax the existing cells in the hearts muscles to produce new heart-muscle cells.

Adult stem cell therapy for treating heart diseases has been examined in medical tests for efficacy as well as adverse effects. These tests have proved that such stem cell therapy is much better and safer than many existing procedures for treating cardiovascular diseases. This is the reason adult stem cell therapy is gaining importance in cardiac stem cell research. The global market for Stem Cells in Cardiology is projected to reach about US$ XX.XX billion by 2015 at a CAGR of about XX.XX % from a market of about US$ XX.XX billion in 2009. Adult stem cells market is the largest tapped market while cord blood and embryonic stem cell markets, though with huge market potential, are still in infancy stages. Embryonic stem cells to treat cardiac disorders is the current topic of Interest. But, due to various ethical origins, is mired in debates all over the world..

http://www.researchimpact.c om/
MIR024 Stem Cells in Cardiology A Market Insight Report, January 2011 RI Technologies, www.researchimpact.com Sample Page - 9